Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab Treat-to-Target Strategy in Crohn's Disease
NCT03107793Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Apr 2017
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of ustekinumab in Crohn's disease, sponsored by Janssen-Cilag. Started Apr 2017; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03107793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107793.